BREAST CANCER

Targeted Intraoperative Radiotherapy Concurrent With Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Local Breast Cancer Recurrence

19 November 2013

 

In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in women with breast cancer. Targeted intraoperative radiotherapy met the noninferiority margin for 5-year local recurrence among all patients and when given concurrently with lumpectomy but not when delayed until after lumpectomy (postpathology). Breast cancer mortality did not differ significantly between the two groups, but targeted intraoperative radiotherapy was associated with reduced non–breast cancer mortality.

 

Read More

 

Few Benefit From Contralateral Breast Removal, Model ShowsMisconceptions Leading to More Women Choosing Prophylactic Procedure

November 2013

 

Misconceptions Leading to More Women Choosing Prophylactic Procedure

 

Washington—Of the thousands of women with early-stage breast cancer in one breast who opt to undergo a contralateral prophylactic mastectomy every year, less than one in 100 will derive any survival benefit from the procedure, a new computer model suggests.

 

“We hope that by providing women with accurate and easily understood information about the potential benefits for contralateral prophylactic mastectomy [CPM], this may impact current trends,” said study co-author Pamela Portschy, MD, a surgical resident at the University of Minnesota, Minneapolis.

 

Read More

 

Strong Showing for Ado-Trastuzumab Emtansine in Advanced HER2-Positive Heavily Pretreated Breast Cancer

15 November 2013

 

Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab emtansine (Kadcyla), formerly known as T-DM1, extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab (Herceptin) and lapatinib (Tykerb). The findings were presented at the European Cancer Congress 2013 in Amsterdam.

 

Read More

 

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists ClinicalPractice Guideline Update

7 October 2013

 

Purpose - To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP)guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancerto improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.

 

Read More

 

First pre-surgery breast cancer drug approved by FDA

2 October 2013

 

The US Food and Drug Administration (FDA) has approved the first drug to be used in early stage breast cancer treatment. Perjeta (pertuzumab) will be used as part of a complete treatment regimen for patients before surgery (neoadjuvant setting).

 

Read More
 
Breast cancer spread: clues found in molecular switch

30 September 2013

 

Using state of the art technology, researchers at the University of Copenhagen in Denmark have pinpointed molecular mechanisms that they suspect play an important role in breast cancer cell growth and spread (metastasis).

 

Read More

INTERNATIONAL NEWS

LUNG CANCERS

FDA Grants Regular Approval to Crizotinib for ALK-Positive NSCLC

21 November 2013

 

The U.S. Food and Drug Administration (FDA) today granted regular approval for crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Today’s approval was based on demonstration of superior progression-free survival and overall response rate for crizotinib-treated patients compared to chemotherapy in patients with ALK-positive NSCLC with disease progression after platinum-based doublet chemotherapy.
Crizotinib was previously granted accelerated approval in August 2011 based on durable objective response rates of 50% and 61% in two single-arm, open-label studies.

 

Read More

 

LUX-Lung 3: Afatinib Prolongs Progression-free Survival vs Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma 

15 August 2013

 

Afatinib (Gilotrif) is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma showed high response rates and progression-free survival.

 

Read More

 

GASTROINTESTINAL CANCERS

12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer

22 November 2013

 

In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer recurrence score in patients with stage II or III colon cancer who were treated with fluorouracil (5-FU) with or without oxaliplatin. They found that the recurrence score is an independent predictor of recurrence in this setting and that it provides predictive information beyond standard clinical and pathologic risk factors.

 

Read More

 

HEAD AND NECK CANCERS

FDA approves Sorafenib to treat late stage thyroid cancer

22 November 2013

 

The U.S. Food and Drug Administration today expanded the approved uses of sorafenib (Nexavar) to treat late-stage differentiated thyroid cancer. The new indication is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive iodine treatment.

 

Read More

 

New marker for thyroid cancer recurrence identified

28 October 2013

 

High levels of two microRNA molecules within papillary thyroid cancer tumours predict recurrence after surgery, according to new Australian research.

 

Read More

GYNECOLOGICAL CANCERS 

Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer

22 November 2013

 

In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation could potentially be employed as a biomarker for early detection of endometrial cancer and as a predictor of treatment response.

 

Read More

 

 

Brivanib Studied in First- and Second-Line Therapy for Advanced Hepatocellular Carcinoma 

15 November 2013

 

 

The investigational drug brivanib is a dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. The agent was recently evaluated in two phase III trials, one comparing first-line brivanib with sorafenib (Nexavar) in advanced hepatocellular carcinoma (BRISK-FL trial) and one comparing brivanib plus best supportive care vs placebo plus best supportive care in patients with advanced hepatocellular carcinoma in whom sorafenib therapy failed or was not tolerated (BRISK-PS trial).

 

Read More

 

NEURO-ONCOLOGY

12 November 2013

TWEAK-Fn14 a key drug target for glioblastoma and other cancers

 

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute (TGen).

 

Read More

 

GENITOURINARY CANCERS 

Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer

20 November 2013

 

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.

 

Read More

 

SKIN CANCERS

Additional Interim Data for Lambrolizumab Show Survival Benefit for Patients With Advanced Melanoma

19 November 2013

 

Read More

OTHERS

05 November 2013

Nanotechnology infiltrates and quashes aggressive cancers that survive traditional therapy

 

The latest Cancer / Oncology News articles published daily. Includes news on the physical, chemical and biologic properties and features of neoplasms, tumors, symptoms, treatments, causes and risk factors.

 

Read More

 

Red wine chemical resveratrol remains effective against cancer after the body converts it

05 October 2013

 

A chemical found in red wine remains effective at fighting cancer even after the body's metabolism has converted it into other compounds.

 

Read More

 

ASCO Studies Support Limited Use of 'Routine' Imaging

15 August 2013

 

The overuse of imaging in oncology workup and surveillance is a timely concern, as health-care dollars shrink and the risk for second malignancies becomes clearer. At this year’s ASCO Annual Meeting, several studies showed that although many routine imaging studies may be unnecessary, physicians can be slow to adopt new recommendations.

 

Read More

 

Secretariat

Email: sso@globewerks.com 

Tel: (65) 6513 7310

Fax: (65) 6659 8946

Address: 22 Sin Ming Lane, #03-85 Midview City, Singapore 573969

Monday -  Friday    9:00 am - 6.00  pm
Saturday, Sunday & Public Holiday closed. 

  • Facebook Social Icon